Less than a week into his tenure as Disney's newly-appointed CEO , Josh D'Amaro is already dealing with two separate crises that have cast a shadow over the company's future plans. OpenAI is shutting down its Sora image-generation program just months after Disney announced a $1 billion dollar collaboration to bake the tech into Disney Plus . And Fortnite maker Epic is laying off 1,000 employees at...
Less than a week into his tenure as Disney's newly-appointed CEO , Josh D'Amaro is already dealing with two separate crises that have cast a shadow over the company's future plans. OpenAI is shutting down its Sora image-generation program just months after Disney announced a $1 billion dollar collaboration to bake the tech into Disney Plus . And Fortnite maker Epic is laying off 1,000 employees at a time when we've heard basically nothing about the game studio's $1.5 billion investment deal with Disney to build a metaverse . Disney could still integrate generative AI into its streaming service, and we might end up seeing some version of the co … Read the full story at The Verge.
jabkitticha/iStock via Getty Images Fast Facts iShares MSCI EAFE Min Vol Factor ETF ( EFAV ) was launched on 10/18/2011 and tracks the MSCI EAFE Minimum Volatility Index. EFAV has a portfolio of 243 stocks, a 30-day SEC yield of 2.97%, and an expense ratio of 0.20%. Distributions are paid semi-annually. Strategy As described in the prospectus by iShares , the underlying index starts from the MSCI ...
jabkitticha/iStock via Getty Images Fast Facts iShares MSCI EAFE Min Vol Factor ETF ( EFAV ) was launched on 10/18/2011 and tracks the MSCI EAFE Minimum Volatility Index. EFAV has a portfolio of 243 stocks, a 30-day SEC yield of 2.97%, and an expense ratio of 0.20%. Distributions are paid semi-annually. Strategy As described in the prospectus by iShares , the underlying index starts from the MSCI EAFE Index, designed to measure the performance of developed equity markets outside the United States and Canada. Stocks are selected and weighted by an optimization process aiming at the lowest absolute portfolio volatility under some constraints. These constraints include turnover, minimum and maximum weights of constituents, sectors and countries, liquidity, and financial leverage. EFAV targets low aggregate volatility, not necessarily low-volatility stocks. The index is rebalanced on a quarterly basis, and the portfolio’s turnover rate was 24% in the most recent fiscal year. This article will use as a benchmark the parent index, represented by iShares MSCI EAFE ETF ( EFA ). Portfolio The portfolio is mostly invested in large- and mega-cap companies (about 85% of asset value), with a focus on Japan (27.3%) and notable exposure in Switzerland (10.9%) and the U.K. (9.8%). Other countries are below 7%. Compared to its parent index, EFAV mostly overweights Japan, Hong Kong, and Singapore and significantly downplays the U.K., France, Germany, and the Netherlands. EFAV top 10 countries, % of asset value (Chart: author; data: iShares) EFAV offers a more balanced sector breakdown than EFA by downplaying financials (19.6%) and industrials (14.6%). EFAV sector breakdown, % of asset value (Chart: author; data: iShares) The portfolio is well-diversified, with low company-specific risk. Indeed, the top 10 holdings, listed in the next table, represent 15.2% of asset value, and the largest position weighs 1.63%. Name Sector Country Ticker Weight% SHELL PLC Energy UK SHEL 1.63 TOTALENER...
ConocoPhillips ( COP ) snapped six straight sessions of gains on Wednesday after it ended 0.32% lower at $128.93. The oil major has been closing in the green since March 17. Between March 17 and March 24, the stock gained over 5% compared to more than 2% fall in the broader markets. Investors have been closely watching the movement of oil companies amid the volatility triggered by tensions in the ...
ConocoPhillips ( COP ) snapped six straight sessions of gains on Wednesday after it ended 0.32% lower at $128.93. The oil major has been closing in the green since March 17. Between March 17 and March 24, the stock gained over 5% compared to more than 2% fall in the broader markets. Investors have been closely watching the movement of oil companies amid the volatility triggered by tensions in the Middle East which sent oil prices soaring earlier this month. Goldman Sachs highlighted the company as one of its favorite oil and gas stocks following the U.S.-Israel strikes in Iran, resulting supply disruptions at the Strait of Hormuz. Goldman analysts led by Neil Mehta argued that Conoco presents a compelling free cash flow growth outlook, supporting robust shareholder returns through buybacks and steady dividend growth. Additional upside could emerge if key projects, particularly Willow, align with a prolonged oil upcycle, driven by slowing non-OPEC supply growth and resilient demand, they said. As per Seeking Alpha’s quant ratin g, the stock has a Hold rating with a score of 3.38 out of 5. COP has been rated a D+ for valuation, while it has been graded A+ for profitability. However, both Seeking Alpha and Wall Street analysts have rated the stock as Buy. More on ConocoPhillips ConocoPhillips: Cash-First Upstream Investing Has A Case ConocoPhillips 2025 Q4 - Results - Earnings Call Presentation ConocoPhillips (COP) Q4 2025 Earnings Call Transcript Insider trades: Salesforce, Broadcom among notable names this week Insider trades: Bank of America, Visa among notable names this week
Procter & Gamble (NYSE: PG ) rises after six straight sessions of losses, with the stock closing 0.41% higher at $143.74 on Wednesday. Over the previous six sessions, PG shares have dropped 5.89%, compared with a 2.13% decline in the S&P 500 Index. Similarly, the stock is down 0.44% in 2025, compared with a 4.22% fall in the broader S&P 500. Forward Analytics said that PG benefits from a long divi...
Procter & Gamble (NYSE: PG ) rises after six straight sessions of losses, with the stock closing 0.41% higher at $143.74 on Wednesday. Over the previous six sessions, PG shares have dropped 5.89%, compared with a 2.13% decline in the S&P 500 Index. Similarly, the stock is down 0.44% in 2025, compared with a 4.22% fall in the broader S&P 500. Forward Analytics said that PG benefits from a long dividend track record and strong global brand presence, assigning the stock a Buy rating. The company’s ongoing restructuring is focused on cost efficiencies and long-term growth, with early productivity gains beginning to emerge. However, analysts added that a recovery in volumes remains key to sustaining organic growth, as further price increases could weigh on demand in an inflationary environment. Seeking Alpha analyst Manika Premsingh also rated the stock a Buy, stating that while it underperformed last year, early signs of a recovery are emerging in 2025. Despite risks to sales and earnings from higher oil prices and their impact on consumer spending, she highlighted positives including growth potential, strong margins, perceived undervaluation, steady dividend payouts, and low volatility, which could support momentum in uncertain market conditions. Looking at Seeking Alpha’s Quant rating , PG currently has a Hold rating with a score of 3.23 out of 5. The company was rated A+ for profitability, while it got a D for growth and a D- for valuation. Turning to the Wall Street community , 14 analysts gave PG a Buy and above rating, 9 analysts have given the stock a Hold recommendation, while 1 recommended Sell or lower. However, Seeking Alpha analysts appeared cautious and issued a Hold rating. More on Procter & Gamble The Procter & Gamble Company: Dividend Intact Amid Ongoing Restructuring Procter & Gamble: Uptick Likely Despite Risks Procter & Gamble: Defensive Hedge Against Market Volatility Insider Trades: Boeing, Coca-Cola, Exxon Mobil among notable names Most and least s...
Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S&P 500 . However, ongoing developments suggest that the biotech leader could be staging a rebound, and if it does, now might be a great time to buy the stock. Let's see how things could unfold for Vertex Pharm...
Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S&P 500 . However, ongoing developments suggest that the biotech leader could be staging a rebound, and if it does, now might be a great time to buy the stock. Let's see how things could unfold for Vertex Pharmaceuticals in the next year. Image source: Getty Images. Vertex Pharmaceuticals makes most of its money from the sale of medicines for cystic fibrosis (CF), a rare disease that affects the lungs and other organs and causes difficulty breathing. Vertex Pharmaceuticals' most important therapies for CF are Trikafta, which treats up to 90% of CF patients, and the newer Alyftrek, which offers the added benefit of once-daily dosing. Continue reading
Cognyte Software (NASDAQ: CGNT) was a lively stock on the exchange on Wednesday, and for the right reasons. The Israel-based "investigative analytics" specialist published quarterly and annual results that investors obviously found impressive. As a result, the company's shares closed the day more than 6% higher. Well before market open, Cognyte took the wraps off its fourth-quarter and full-year 2...
Cognyte Software (NASDAQ: CGNT) was a lively stock on the exchange on Wednesday, and for the right reasons. The Israel-based "investigative analytics" specialist published quarterly and annual results that investors obviously found impressive. As a result, the company's shares closed the day more than 6% higher. Well before market open, Cognyte took the wraps off its fourth-quarter and full-year 2026 results. For the quarter, revenue was slightly over $106 million, up 12% year over year. The bottom-line improvement was far more dramatic, with net income not under generally accepted accounting principles (GAAP) almost quadrupling to $7.6 million ($0.10 per share). Image source: Getty Images. Continue reading
Ian Fujiyama, global head of aerospace, defense and government at Carlyle, joins Dani Burger on "Bloomberg Deals." They discuss defense tech investments and the Trump Administration as the Iran War reveals gaps in spending. The Pentagon wants to shift roughly $1.5 billion in previously approved funding to buy critical missile interceptors from Lockheed Martin and RTX, according to the acting compt...
Ian Fujiyama, global head of aerospace, defense and government at Carlyle, joins Dani Burger on "Bloomberg Deals." They discuss defense tech investments and the Trump Administration as the Iran War reveals gaps in spending. The Pentagon wants to shift roughly $1.5 billion in previously approved funding to buy critical missile interceptors from Lockheed Martin and RTX, according to the acting comptroller — weapons that are in short supply as the war in Iran consumes vast amounts of the munitions. (Source: Bloomberg)
A consortium led by Indian billionaire Kumar Mangalam’s Aditya Birla Group, The Times of India Group, David Blitzer’s Bolt Ventures and Blackstone has bought the Royal Challengers Bengaluru, in a major deal for cricket. Bloomberg's Scarlet Fu reports on "Bloomberg Deals." (Source: Bloomberg)
A consortium led by Indian billionaire Kumar Mangalam’s Aditya Birla Group, The Times of India Group, David Blitzer’s Bolt Ventures and Blackstone has bought the Royal Challengers Bengaluru, in a major deal for cricket. Bloomberg's Scarlet Fu reports on "Bloomberg Deals." (Source: Bloomberg)
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with de...
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible steward of investor capital, and continued to advance our CAR-NK cell therapy platform through dose escalation in the clinic,” said Paul J. Hastings, Chief Executive Officer of Nkarta. “Thoughtfully leveraging our safety data, we are now dosing patients at 4 billion cells in a three-dose cycle for a total of 12 billion cells as we look to maximize the depth and durability of B-cell depletion and clinical response, positioning us to unlock the full potential of NKX019 for people living with autoimmune disease.”
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2025, and other recent business developments.
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2025, and other recent business developments.
The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Commercial Metals Company (CMC)is reporting for the quarter ending February 28, 2026. The steel company's consens
The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Commercial Metals Company (CMC)is reporting for the quarter ending February 28, 2026. The steel company's consens
Honda Motor Co. ’s costly misfire on electric cars has dramatically increased the stakes for the company to avoid making the same mistakes with motorcycles. Almost one out of every three motorcycles sold globally is a Honda, generating the majority of the manufacturer’s operating profit despite accounting for less than a fifth of sales. Even so, cracks are starting to appear as e-bikes from China ...
Honda Motor Co. ’s costly misfire on electric cars has dramatically increased the stakes for the company to avoid making the same mistakes with motorcycles. Almost one out of every three motorcycles sold globally is a Honda, generating the majority of the manufacturer’s operating profit despite accounting for less than a fifth of sales. Even so, cracks are starting to appear as e-bikes from China encroach on its turf. Though cars will undoubtedly be the focus of Chief Executive Officer Toshihiro Mibe ’s turnaround plan in May, he will also face pressure to show investors he won’t squander Honda’s best-performing unit. How the company adapts to an electric future will be central to whether it can stabilize earnings and restore investor confidence. “What’s happening with automobiles is the most likely scenario for two-wheelers,” said Hikaru Todoroki, principal auto consultant for KPMG. “Competition is intensifying.” Read More: Honda Could Get BYD-ed in Key Scooter Market: David Fickling A spokesperson for Honda declined to comment on electrification and motorcycles. Honda’s motorcycle business is already encountering growing competition. The manufacturer began its global electric motorcycle rollout three years ago with two models each in Indonesia and India, but the South Asian debut struggled. Of the two introduced in India, one relied on battery swapping without home charging, limiting usability, while the other paired fast charging with a significantly higher price than rivals. India, which accounts for roughly a third of the global motorcycle market, has drawn a wave of competitors racing to introduce new models, advance technology and secure battery supplies largely controlled by China and South Korea. Apart from Yadea Group Holdings Ltd. , the world’s largest electric bike maker by volume, newcomers such as VinFast Auto Ltd. in Vietnam, Gogoro Inc. in Taiwan and Bajaj Auto Ltd. in India are all seeking to expand their footprint. “Making an aggressive effort to a...
Ekaterina79/iStock via Getty Images The consensus remains bullish on inflationary expectations, including precious metals, stocks, and oil. But then, recency bias is the typical human response. It’s worth considering that cycle peaks could be behind us. Gold pared dramatic losses as US President Donald Trump postponed military strikes against Iranian energy infrastructure for a five-day period aft...
Ekaterina79/iStock via Getty Images The consensus remains bullish on inflationary expectations, including precious metals, stocks, and oil. But then, recency bias is the typical human response. It’s worth considering that cycle peaks could be behind us. Gold pared dramatic losses as US President Donald Trump postponed military strikes against Iranian energy infrastructure for a five-day period after what he described as productive talks toward ending hostilities. Oil also fell sharply, posting one of the biggest intraday price swings on record, after President Donald Trump postponed strikes on Iranian power plants and said his team held discussions about ending the conflict, though Tehran denied any such dialog. Bloomberg’s Mike McGlone joins to discuss on Bloomberg Intelligence. Here is a direct video link. As prices fall, leveraged participants necessitate selling across all assets to pay down margin debt (shown in red below since 1995, with the S&P 500 price in black). Longer-term support tests remain far below current levels (S&P 500 shown below since the end of 2019, courtesy of Bespoke). Food for thought when reviewing one’s risk management plans and assumptions. Most people have no idea that current stock valuation extremes mean prices can halve and remain within a secular uptrend. Disclosure: No positions Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.